文献速递外周动脉疾病

下肢跛行患者EVT术后LDL-C水平与5年心血管死亡的关系

Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
PubMed 文献 · J Endovasc Ther · 2019-03-15

本研究纳入935例因跛行(Rutherford 1-3级)接受EVT的下肢PAD患者,分析EVT后3-6个月LDL-C水平与5年心血管死亡的关系。中位随访30.7个月,CVD发生83例(8.9%);LDL-C≥100 mg/dL者5年CVD发生率显著高于<100 mg/dL者(23.5% vs 13.5%,p=0.03),尤其在他汀治疗患者中(25.2% vs 10.9%,p=0.02)。多因素分析显示LDL-C≥100 mg/dL是CVD独立预测因子(调整HR 1.60,95%CI 1.001-2.59,p=0.049)。

要点

  • EVT术后3-6个月LDL-C≥100 mg/dL与5年心血管死亡风险独立相关。
  • 出院时接受他汀治疗者中,LDL-C≥100 mg/dL者CVD发生率更高。
  • 结果提示可能需要强化降LDL-C治疗以改善临床结局。

核心结论

  • 对有症状下肢PAD行EVT的患者,术后3-6个月LDL-C≥100 mg/dL与5年心血管死亡风险升高独立相关,尤其见于出院时接受他汀治疗者。

研究设计与样本

  • 回顾性队列研究,2010年1月至2016年3月共1324例跛行(Rutherford 1-3级)PAD患者(1670条肢体)接受EVT。
  • 排除389例因死亡或数据缺失后,最终分析935例(70.6%),平均年龄72.1±8.7岁,男性708例。
  • 出院时509例(54.4%)接受他汀治疗。
  • 以队列LDL-C中位数94 mg/dL为参考,采用100 mg/dL作为分层因素。

主要发现

  • 中位随访30.7个月(四分位距13.7-47.6),心血管死亡发生83例(8.9%)。
  • EVT后3-6个月LDL-C≥100 mg/dL者5年CVD发生率为23.5%,LDL-C<100 mg/dL者为13.5%(p=0.03)。
  • 在509例出院时接受他汀治疗的患者中,LDL-C≥100 mg/dL者CVD发生率为25.2%,<100 mg/dL者为10.9%(p=0.02)。
  • 多因素模型中,EVT后3-6个月LDL-C≥100 mg/dL是CVD的独立预测因子(调整HR 1.60,95%CI 1.001-2.59,p=0.049)。

临床怎么用

  • 对下肢跛行EVT术后患者,应在术后3-6个月检测LDL-C,关注是否达到<100 mg/dL。
  • 出院时已接受他汀治疗但LDL-C仍≥100 mg/dL者CVD风险更高,提示需考虑强化降脂治疗。

局限性

  • 排除389例因死亡或数据缺失的患者,可能引入选择偏倚。
  • LDL-C分层阈值100 mg/dL基于队列中位数94 mg/dL设定。
  • 研究为观察性设计,残余混杂可能影响关联估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the association between low-density lipoprotein cholesterol (LDL-C) levels and the 5-year cardiovascular death rate after endovascular therapy (EVT) in patients with lower limb peripheral artery disease (PAD) according to statin therapy status. METHODS: From January 2010 to March 2016, 1324 PAD patients (1670 limbs) with claudication (Rutherford category 1-3) underwent EVT. After excluding 389 patients owing to death or missing data, 935 (70.6%) patients (mean age 72.1±8.7 years; 708 men) were included in the analysis. Statin therapy was prescribed to 509 (54.4%) patients at discharge. LDL-C levels at 3 to 6 months after EVT were correlated with the incidence of cardiovascular death (CVD; procedure-related and proximate cardiac, noncoronary vascular, or unknown causes) at 5 years. A stratifying factor of 100 mg/dL was based on the median LDL-C value (94 mg/dL) in the cohort. Predictors of CVD were sought in multivariate analysis; results are presented as the hazard ratio (HR) and 95% confidence interval (CI). RESULTS: Over a median follow-up of 30.7 months (interquartile range 13.7, 47.6), CVD occurred in 83 (8.9%) patients. The incidence of CVD at 5 years was significantly higher in patients with LDL-C ≥100 mg/dL at 3 to 6 months than in those with LDL-C <100 mg/dL (23.5% vs 13.5%, p=0.03). In addition, LDL-C ≥100 mg/dL at 3 to 6 months was associated with a higher incidence of CVD (25.2% vs 10.9%, p=0.02) in 509 (54.4%) patients with statin therapy at discharge. In the multivariate model, LDL-C ≥100 mg/dL at 3 to 6 months after EVT was an independent predictor of CVD (adjusted HR 1.60, 95% CI 1.001 to 2.59, p=0.049). CONCLUSION: LDL-C ≥100 mg/dL at 3 to 6 months after the EVT for symptomatic lower limb PAD was independently associated with a higher risk of CVD, particularly in patients on statin therapy at discharge. This observation suggests that intensive LDL-C-lowering therapy may be needed to improve clinical outcomes.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tomoi Y, Yamaji K, Soga Y, et al. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. J Endovasc Ther. 2019. PMID: 30873910. doi:10.1177/1526602819836382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。